Ivonescimab

Overview

No overview information available.

Indication

本品联合培美曲塞和卡铂，用于经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）患者的治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer	2025/08/11	NCT07114315	Not Applicable	Not yet recruiting	Akeso
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	2025/07/30	NCT07094685	Not Applicable	Not yet recruiting	University of Michigan Rogel Cancer Center
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	2025/07/17	NCT07070466	Not Applicable	Not yet recruiting	Massachusetts General Hospital
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial	2025/07/17	NCT07070479	Not Applicable	Recruiting	Ming-Yuan Chen
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.	2025/07/04	NCT07052253	Not Applicable	Not yet recruiting	Akeso
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1	2025/06/26	NCT07038915	Phase 2	Withdrawn	M.D. Anderson Cancer Center
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer	2025/06/15	NCT07021950	Phase 2	Not yet recruiting	Sun Yat-sen University
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	2025/06/12	NCT07017673	Phase 2	Recruiting	Cedars-Sinai Medical Center
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy	2025/06/08	NCT07010263	Phase 3	Not yet recruiting	Akeso
Ivonescimab for the Treatment of Thymic Cancer	2025/05/20	NCT06980077	Phase 2	Recruiting	Jonsson Comprehensive Cancer Center

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Akeso Reports Record Sales Growth as Ivonescimab Meets Overall Survival Endpoint in Phase III Trial

9 days ago

Akeso's commercial sales surged 49.20% to RMB 1,401.6 million in the first half of 2025, driven by expanded indications and NRDL inclusion for its bispecific antibodies.

IO Biotech's Melanoma Vaccine Narrowly Misses Primary Endpoint in Phase 3 Trial Despite Promising Subgroup Results

24 days ago

IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.

Compass Therapeutics Reports Promising Clinical Data Across Bispecific Antibody Pipeline

25 days ago

Compass Therapeutics' tovecimig met its primary endpoint in Phase 2/3 biliary tract cancer trial, with fewer deaths observed than projected suggesting potential overall survival benefit.

Ivonescimab Demonstrates Superior Efficacy in Phase III Lung Cancer Trials, Positioning for Global Regulatory Approvals

a month ago

Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.

Sino Biopharmaceutical Acquires LaNova Medicines for $951 Million, Targeting PD-1xVEGF Cancer Therapies

2 months ago

Sino Biopharmaceutical announced plans to acquire LaNova Medicines for up to $951 million, with a net payment of approximately $500 million after accounting for cash holdings.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access